Michael B. Lilly
Professor of Clinical Medicine
Vice Chief for Clinical Programs
School of Medicine
School of Medicine
M.D., Loma Linda University, 1975
B.A., Southern Adventist University, 1971, Biology, Chemistry
B.A., Southern Adventist University, 1971, Biology, Chemistry
University of California, Irvine
Bldg 56 Rm 248 Rt 81
Mail Code: 4061
Orange, CA 92868
Bldg 56 Rm 248 Rt 81
Mail Code: 4061
Orange, CA 92868
Research Interests
Urologic Malignancy (prostate, testis, kidney, bladder) Hematologic Malignancy
Academic Distinctions
Alpha Omega Alpha(1974)
National Research Service Fellow(1980)
Fellow, American College of Physicians (1981)
National Research Service Fellow(1980)
Fellow, American College of Physicians (1981)
Publications
Lilly M, Zemskova M, Frankel AE, Salo J, Kraft AS: Distinct domains of the human GM-CSF receptor alpha subunit mediate activation of JAK/STAT signaling and differentiation. Blood 97:1662-1670, 2001.
Wu X, Daniels T, Molinaro C, Lilly MB, Casiano C: Caspase cleavage of the nuclear autoantigen LEDGF/p75 abrogatres its prosurvival function: implications for autoimmunity in atopic disorders. Cell Death Differentiation 9:915-924 (2002).
Lombano F, Kidder MY, Lilly M, Gollin YG, Block BS: Recurrence of microangiopathic hemolytic anemia after apparent recovery from the HELLP syndrome: A case report. J Reprod Med 47:875-877 (2002)
Frankel AE, Powell BL, Lilly MB. Diphtheria toxin conjugate therapy of cancer.
Cancer Chemother Biol Response Modif. 2002;20:301-13. Review
Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, Kraft AS: Nuclear localization of the pim-1 protein kinase is necessary for its biologic effects. Anticancer Res 23(1A):167-78 (2003).
Yan B, Zemskova M, Holder S, Chin V, Kraft AS, Koskinen PJ, Lilly MB: The PIM-2 kinase phosphorylates BAD on serine-112 and reverses BAD induced cell death. J Biol Chem 278:45358-45367 (2003)
Aho TLT, Sandholm J, Peltola KJ, Mankonen H, Lilly M, Koskinen PJ: Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Letters 571:43-49 (2004).
Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M: Vaccinia virus-mediated p53 gene therapy of bladder cancer in an orthotopic murine model. J Urology 173, 604-609 (2005).
Kim K-T, Baird K, Ahn J-Y, Meltzer P, Lilly M, Small D: Pim-1 is upregulated in constitutively activating FLT3 mutants and plays a role in FLT3-mediated cell survival. Blood 105(4), 1759-1767 (2005).
Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 3:443-51 (2005).
Zemskova M, Wechter W, Yoshida J, Ruckle H, Reiter RE, Lilly MB: Gene expression profiling in R-flurbiprofen-treated prostate cancer: Identification of prostate stem cell antigen as a flurbiprofen-regulated gene. Biochem Pharmacology 72:1257-1267 (2006).
Holder SL, Zemskova M, Bremner R, Neidigh J, Lilly MB: Identification of specific, cell-permeable small molecule inhibitor of the PIM1 kinase. Mol Cancer Therapeutics Mol Cancer Ther. 6:163-72 (2007).
Ma J, Arnold HK, Lilly MB, Sears R, Kraft AS: Negative regulation of PIM-1 protein kinase levels by the B56b subunit of PP2A. Oncogene Feb 12, 2007; [Epub ahead of print]
Hansen JE, Fischer LK, Chan G, Chang SS, Bladwin SW, Aragon RJ, Carter JJ, Lilly MB, Nishimura RN, Weisbart RH, Reeves ME: Antibody-mediated p53 protein therapy prevents liver metastatsis in vivo. Cancer Res 67:1769-74 (2007).
Holder SL, Lilly MB, Brown ML: Comparative Molecular Field Analysis of Flavonoid Inhibitors of the PIM-1 Kinase. Bioorg Med Chem (in press, 2007)
Zhou J, Pan M, Xie Z, Loh S-L, Bi C, Tai Y-C, Lilly MB, Lim Y-P, Han J-H, Glaser KB, Albert DH, Davidsen SK, Chen CS: Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle regulated genes and c-Mos-mediated MAPK pathway. Leukemia (in press, 2007)
Wu X, Daniels T, Molinaro C, Lilly MB, Casiano C: Caspase cleavage of the nuclear autoantigen LEDGF/p75 abrogatres its prosurvival function: implications for autoimmunity in atopic disorders. Cell Death Differentiation 9:915-924 (2002).
Lombano F, Kidder MY, Lilly M, Gollin YG, Block BS: Recurrence of microangiopathic hemolytic anemia after apparent recovery from the HELLP syndrome: A case report. J Reprod Med 47:875-877 (2002)
Frankel AE, Powell BL, Lilly MB. Diphtheria toxin conjugate therapy of cancer.
Cancer Chemother Biol Response Modif. 2002;20:301-13. Review
Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, Kraft AS: Nuclear localization of the pim-1 protein kinase is necessary for its biologic effects. Anticancer Res 23(1A):167-78 (2003).
Yan B, Zemskova M, Holder S, Chin V, Kraft AS, Koskinen PJ, Lilly MB: The PIM-2 kinase phosphorylates BAD on serine-112 and reverses BAD induced cell death. J Biol Chem 278:45358-45367 (2003)
Aho TLT, Sandholm J, Peltola KJ, Mankonen H, Lilly M, Koskinen PJ: Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Letters 571:43-49 (2004).
Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M: Vaccinia virus-mediated p53 gene therapy of bladder cancer in an orthotopic murine model. J Urology 173, 604-609 (2005).
Kim K-T, Baird K, Ahn J-Y, Meltzer P, Lilly M, Small D: Pim-1 is upregulated in constitutively activating FLT3 mutants and plays a role in FLT3-mediated cell survival. Blood 105(4), 1759-1767 (2005).
Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 3:443-51 (2005).
Zemskova M, Wechter W, Yoshida J, Ruckle H, Reiter RE, Lilly MB: Gene expression profiling in R-flurbiprofen-treated prostate cancer: Identification of prostate stem cell antigen as a flurbiprofen-regulated gene. Biochem Pharmacology 72:1257-1267 (2006).
Holder SL, Zemskova M, Bremner R, Neidigh J, Lilly MB: Identification of specific, cell-permeable small molecule inhibitor of the PIM1 kinase. Mol Cancer Therapeutics Mol Cancer Ther. 6:163-72 (2007).
Ma J, Arnold HK, Lilly MB, Sears R, Kraft AS: Negative regulation of PIM-1 protein kinase levels by the B56b subunit of PP2A. Oncogene Feb 12, 2007; [Epub ahead of print]
Hansen JE, Fischer LK, Chan G, Chang SS, Bladwin SW, Aragon RJ, Carter JJ, Lilly MB, Nishimura RN, Weisbart RH, Reeves ME: Antibody-mediated p53 protein therapy prevents liver metastatsis in vivo. Cancer Res 67:1769-74 (2007).
Holder SL, Lilly MB, Brown ML: Comparative Molecular Field Analysis of Flavonoid Inhibitors of the PIM-1 Kinase. Bioorg Med Chem (in press, 2007)
Zhou J, Pan M, Xie Z, Loh S-L, Bi C, Tai Y-C, Lilly MB, Lim Y-P, Han J-H, Glaser KB, Albert DH, Davidsen SK, Chen CS: Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle regulated genes and c-Mos-mediated MAPK pathway. Leukemia (in press, 2007)
Zemskova M, Sahakian E, Bashkirova S, Lilly MB. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem. 2008 Jul 25;283(30):20635-44. Epub 2008 Apr 21.
Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB, Salto-Tellez M. Potential roles for the PIM1 kinase in human cancer - A molecular and therapeutic appraisal. Eur J Cancer. 2008 Aug 18. [Epub ahead of print]
Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA: Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Investigation 2008 Sep;118(9):3038-50.
Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther. 2009 May 18;8(9).
Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2009 Dec 15. [Epub ahead of print] PubMed PMID: 20131302.
Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S,Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010 Feb;16(2):205-13.
Grants
Department of Defense, CDMRP Prostate Cancer Program PC040635 Pim-1: A Molecular Target to Modulate Cellular Resistance to Therapy in Prostate Cancer
Professional Societies
American Society of Hematology
American Society for Bone Marrow Transplantation
American Society of Gene Therapy
Other Experience
Co-leader for Translational Oncology Program
UCI 2006—pres
UCI 2006—pres
Medical Director, Chao Family Comprehensive Cancer
UCI 2007—pres
UCI 2007—pres
Research Centers
Chao Family Comprehensive Cancer Center
Link to this profile
https://faculty.uci.edu/profile/?facultyId=5536
https://faculty.uci.edu/profile/?facultyId=5536
Last updated
04/19/2010
04/19/2010